Consolidated Financial Results for the Three Months ended June 30, 2026 (FY2026) (Japanese standard)7/30 15:30TDnetPDF(362KB)
Notice Regarding the Completion of Payment for the Disposition of Treasury Stock as Restricted Stock Compensation7/22 16:00TDnetPDF(227KB)
JCR Pharmaceuticals Announces Development Plan in Japan for Givinostat for Duchenne Muscular Dystrophy7/15 8:30TDnetPDF(205KB)
Partial Correction: Consolidated Financial Results for the Full Year ended March 31, 2026 (FY2025)(Japanese standard) 6/23 16:00TDnetPDF(641KB)
Partial Correction: Consolidated Financial Results for the Full Year ended March 31, 2025 (FY2024)(Japanese standard) 6/23 16:00TDnetPDF(529KB)
Notice Regarding the Disposition of Treasury Stock as Restricted Stock Compensation6/23 16:00TDnetPDF(273KB)
ムコ多糖症関連国際シンポジウム(18th International Symposium on MPS and Related Lysosomal Diseases 2026)における発表内容のご報告6/8 13:00TDnetPDF(306KB)
Other Matters Subject to Measures for Electronic Provision When Convening the 51st Ordinary General Meeting of Shareholders6/1 8:00TDnetPDF(284KB)
ムコ多糖症関連国際シンポジウム(18th International Symposium on MPS and Related Lysosomal Diseases 2026)における発表のお知らせ5/28 16:00TDnetPDF(264KB)